In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

被引:51
作者
Laverdiere, M
Hoban, D
Restieri, C
Habel, F
机构
[1] Hop Maison Neuve Rosemont, Dept Microbiol Infect Dis, Montreal, PQ H1T 2M4, Canada
[2] Ctr Hlth Sci, Dept Microbiol, Winnipeg, MB, Canada
关键词
D O I
10.1093/jac/dkf074
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activities of voriconazole, posaconazole, ravuconazole and micafungin were compared with those of fluconazole, itraconazole, ketoconazole, flucytosine and amphotericin B against 164 candidaemia isolates recovered from cancer patients in two Canadian centres. The MIC50 results for ravuconazole, voriconazole, posaconazole and micafungin were 0.01, 0.03, 0.12 and 0.25 mg/L, respectively. The new antifungal agents showed substantial activity against isolates demonstrating in vitro resistance to fluconazole and itraconazole. These results suggest that the newer antifungal agents possess promising activity against invasive Candida isolates, particularly against those with reduced susceptibility to fluconazole and itraconazole.
引用
收藏
页码:119 / 123
页数:5
相关论文
共 10 条
[1]   Quality control limits for broth microdilution susceptibility tests of ten antifungal agents [J].
Barry, AL ;
Pfaller, MA ;
Brown, SD ;
Espinel-Ingroff, A ;
Ghannoum, MA ;
Knapp, C ;
Rennie, RP ;
Rex, JH ;
Rinaldi, MG .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (09) :3457-3459
[2]   Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B [J].
Cuenca-Estrella, M ;
Mellado, E ;
Díaz-Guerra, TM ;
Monzón, A ;
Rodríguez-Tudela, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (03) :475-477
[3]  
Fung-Tomc JC, 1998, ANTIMICROB AGENTS CH, V42, P313
[4]  
HONG M, 1996, AM J MED, V100, P617
[5]  
HONGNUGYEN M, 1998, J ANTIMICROB CHEMOTH, V42, P253
[6]   In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide [J].
Mikamo, H ;
Sato, Y ;
Tamaya, T .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (03) :485-487
[7]  
NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS-NCCLS, 1997, M27A NCCLS
[8]   In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole [J].
Pfaller, MA ;
Messer, SA ;
Hollis, RJ ;
Jones, RN ;
Doern, GV ;
Brandt, ME ;
Hajjeh, RA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) :3242-3244
[9]   DETECTION OF AMPHOTERICIN B-RESISTANT CANDIDA ISOLATES IN A BROTH-BASED SYSTEM [J].
REX, JH ;
COOPER, CR ;
MERZ, WG ;
GALGIANI, JN ;
ANAISSIE, EJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :906-909
[10]   Predictors of outcome in cancer patients with candidemia [J].
Uzun, O ;
Anaissie, EJ .
ANNALS OF ONCOLOGY, 2000, 11 (12) :1517-1521